Literature DB >> 20590618

The role of nitric oxide, superoxide and peroxynitrite in the anti-arrhythmic effects of preconditioning and peroxynitrite infusion in anaesthetized dogs.

Attila Kiss1, László Juhász, György Seprényi, Krisztina Kupai, József Kaszaki, Agnes Végh.   

Abstract

BACKGROUND AND
PURPOSE: Both ischaemia preconditioning (PC) and the intracoronary infusion of peroxynitrite (PN) suppress ischaemia and reperfusion (I/R)-induced arrhythmias and the generation of nitrotyrosine (NT, a marker of PN). However, it is still unclear whether this latter effect is due to a reduction in nitric oxide (NO) or superoxide (O(2)(-)) production. EXPERIMENTAL APPROACH: Dogs anaesthetized with chloralose and urethane were infused, twice for 5 min, with either saline (control) or 100 nM PN, or subjected to similar periods of occlusion (PC), 5 min prior to a 25 min occlusion and reperfusion of the left anterior descending coronary artery. Severities of ischaemia and ventricular arrhythmias, as well as changes in the coronary sinus nitrate/nitrite (NOx) levels were assessed throughout the experiment. The production of myocardial NOx, O(2)(-) and NT was determined following reperfusion. KEY
RESULTS: Both PC and PN markedly suppressed the I/R-induced ventricular arrhythmias, compared to the controls, and increased NOx levels during coronary artery occlusion. Reperfusion induced almost the same increases in NOx levels in all groups, but superoxide production and, consequently, the generation of NT were significantly less in PC- and PN-treated dogs than in controls. CONCLUSIONS AND IMPLICATIONS: Since both PC and the administration of PN enhanced NOx levels during I/R, the attenuation of endogenous PN formation in these dogs is primarily due to a reduction in the amount of O(2) produced. Thus, the anti-arrhythmic effect of PC and PN can almost certainly be attributed to the preservation of NO availability during myocardial ischaemia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20590618      PMCID: PMC2936034          DOI: 10.1111/j.1476-5381.2010.00774.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  50 in total

1.  Activation of nitric oxide synthase by ischaemia in the perfused heart.

Authors:  C Depré; L Fiérain; L Hue
Journal:  Cardiovasc Res       Date:  1997-01       Impact factor: 10.787

2.  Significant levels of oxidants are generated by isolated cardiomyocytes during ischemia prior to reperfusion.

Authors:  T L Vanden Hoek; C Li; Z Shao; P T Schumacker; L B Becker
Journal:  J Mol Cell Cardiol       Date:  1997-09       Impact factor: 5.000

3.  N-2-mercaptopropionylglycine, a scavanger of reactive oxygen species, does not modify the early antiarrhythmic effect of ischaemic preconditioning in anaesthetised dogs.

Authors:  Hajnal Agnes; László Nagy; James R Parratt; Julius Papp; Agnes Végh
Journal:  Cardiovasc Drugs Ther       Date:  2004-11       Impact factor: 3.727

Review 4.  The ubiquitous role of nitric oxide in cardioprotection.

Authors:  Steven P Jones; Roberto Bolli
Journal:  J Mol Cell Cardiol       Date:  2005-11-08       Impact factor: 5.000

5.  L-arginine enhances functional recovery and Ca(2+)-dependent nitric oxide synthase activity after ischemia and reperfusion in the rat heart.

Authors:  Q D Wang; E Morcos; P Wiklund; J Pernow
Journal:  J Cardiovasc Pharmacol       Date:  1997-02       Impact factor: 3.105

6.  Nitric oxide inactivates NADPH oxidase in pig neutrophils by inhibiting its assembling process.

Authors:  H Fujii; K Ichimori; K Hoshiai; H Nakazawa
Journal:  J Biol Chem       Date:  1997-12-26       Impact factor: 5.157

7.  Inhibition of xanthine oxidase and xanthine dehydrogenase by nitric oxide. Nitric oxide converts reduced xanthine-oxidizing enzymes into the desulfo-type inactive form.

Authors:  K Ichimori; M Fukahori; H Nakazawa; K Okamoto; T Nishino
Journal:  J Biol Chem       Date:  1999-03-19       Impact factor: 5.157

8.  Peroxynitrite reduces myocardial infarct size and preserves coronary endothelium after ischemia and reperfusion in cats.

Authors:  T O Nossuli; R Hayward; R Scalia; A M Lefer
Journal:  Circulation       Date:  1997-10-07       Impact factor: 29.690

9.  Intra-coronary administration of L-arginine aggravates myocardial stunning through production of peroxynitrite in dogs.

Authors:  E Mori; N Haramaki; H Ikeda; T Imaizumi
Journal:  Cardiovasc Res       Date:  1998-10       Impact factor: 10.787

10.  Myocardial release of nitric oxide during ischaemia and reperfusion: effects of L-arginine and hypercholesterolaemia.

Authors:  Ananth M Prasan; Hugh C K McCarron; Yi Zhang; Richmond W Jeremy
Journal:  Heart Lung Circ       Date:  2007-04-08       Impact factor: 2.975

View more
  4 in total

1.  Effect of sodium nitrite on ischaemia and reperfusion-induced arrhythmias in anaesthetized dogs: is protein S-nitrosylation involved?

Authors:  Mária Kovács; Attila Kiss; Márton Gönczi; Gottfried Miskolczi; György Seprényi; József Kaszaki; Mark J Kohr; Elizabeth Murphy; Ágnes Végh
Journal:  PLoS One       Date:  2015-04-24       Impact factor: 3.240

2.  Characteristics of inflammatory reactions during development of liver abscess in hamsters inoculated with Entamoeba nuttalli.

Authors:  Yue Guan; Meng Feng; Xiangyang Min; Hang Zhou; Yongfeng Fu; Hiroshi Tachibana; Xunjia Cheng
Journal:  PLoS Negl Trop Dis       Date:  2018-02-08

3.  Regulation of gap junctions by nitric oxide influences the generation of arrhythmias resulting from acute ischemia and reperfusion in vivo.

Authors:  Agnes Végh; Márton Gönczi; Gottfried Miskolczi; Mária Kovács
Journal:  Front Pharmacol       Date:  2013-06-14       Impact factor: 5.810

4.  Examination of the Role of Mitochondrial Morphology and Function in the Cardioprotective Effect of Sodium Nitrite Administered 24 h Before Ischemia/Reperfusion Injury.

Authors:  Vivien Demeter-Haludka; Mária Kovács; Alexandra Petrus; Roland Patai; Danina M Muntean; László Siklós; Ágnes Végh
Journal:  Front Pharmacol       Date:  2018-03-28       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.